DE69110281D1 - Aus einem nichteinheitlichen bläschen bestehende liposomen. - Google Patents

Aus einem nichteinheitlichen bläschen bestehende liposomen.

Info

Publication number
DE69110281D1
DE69110281D1 DE69110281T DE69110281T DE69110281D1 DE 69110281 D1 DE69110281 D1 DE 69110281D1 DE 69110281 T DE69110281 T DE 69110281T DE 69110281 T DE69110281 T DE 69110281T DE 69110281 D1 DE69110281 D1 DE 69110281D1
Authority
DE
Germany
Prior art keywords
emulsion
liposomes containing
vial
composition
addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69110281T
Other languages
English (en)
Other versions
DE69110281T2 (de
Inventor
Sinil Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Depotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depotech Corp filed Critical Depotech Corp
Publication of DE69110281D1 publication Critical patent/DE69110281D1/de
Application granted granted Critical
Publication of DE69110281T2 publication Critical patent/DE69110281T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
DE69110281T 1990-03-21 1991-03-20 Aus einem nichteinheitlichen bläschen bestehende liposomen. Expired - Lifetime DE69110281T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49684690A 1990-03-21 1990-03-21
PCT/US1991/001849 WO1991014445A1 (en) 1990-03-21 1991-03-20 Heterovesicular liposomes

Publications (2)

Publication Number Publication Date
DE69110281D1 true DE69110281D1 (de) 1995-07-13
DE69110281T2 DE69110281T2 (de) 1995-11-09

Family

ID=23974416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69110281T Expired - Lifetime DE69110281T2 (de) 1990-03-21 1991-03-20 Aus einem nichteinheitlichen bläschen bestehende liposomen.

Country Status (20)

Country Link
EP (1) EP0524968B1 (de)
JP (1) JP3461000B2 (de)
KR (1) KR100203223B1 (de)
CN (1) CN1053101C (de)
AT (1) ATE123412T1 (de)
AU (1) AU655177B2 (de)
CA (1) CA2078666C (de)
DE (1) DE69110281T2 (de)
DK (1) DK0524968T3 (de)
ES (1) ES2073164T3 (de)
FI (1) FI104464B (de)
IE (1) IE62772B1 (de)
IL (1) IL97615A (de)
NO (1) NO304576B1 (de)
NZ (1) NZ237464A (de)
PT (1) PT97101B (de)
RU (1) RU2120795C1 (de)
SA (1) SA93130496B1 (de)
WO (1) WO1991014445A1 (de)
ZA (1) ZA911974B (de)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3278273B2 (ja) * 1993-12-17 2002-04-30 キヤノン株式会社 薬剤徐放性カプセル
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
JP4275741B2 (ja) 1996-12-13 2009-06-10 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 血小板由来増殖因子タンパク質の分析および分離
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
EP1014946B1 (de) 1997-09-18 2010-04-07 Pacira Pharmaceuticals, Inc. Retardierte freisetzung liposmaler anesthetischer zusammensetzungen.
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
EP1030652B1 (de) 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Herstellung von multivesikulären liposomen
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
EP1645631B1 (de) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria Meningitidis Antigene und Zusammenstellungen
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
ATE408695T1 (de) 1998-12-16 2008-10-15 Novartis Vaccines & Diagnostic Menschliche cyclin-abhängige kinase (hpnqalre)
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
MXPA02006962A (es) 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
EP2075255A1 (de) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Menschliche FGF-23-Gene und Genexpressionsprodukte
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1370684B1 (de) 2000-06-15 2008-05-28 Novartis Vaccines and Diagnostics, Inc. Polynukleotide zur bestimmung von kolonkrebs
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US7309783B2 (en) 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
EP1404713A4 (de) 2001-05-24 2004-09-22 Human Dna Technology Inc Neues keratinocyte growth factor 2 analogon in haarfollikeln
CA2465953A1 (en) 2001-11-09 2003-05-15 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
EP2335724A1 (de) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
SG148035A1 (en) 2002-01-08 2008-12-31 Novartis Vaccines & Diagnostic Gene products differentially expressed in cancerous breast cells and their methods of use
JP2005520543A (ja) 2002-03-21 2005-07-14 サイグレス ディスカバリー， インコーポレイテッド 癌における新規組成物および方法
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1575517B1 (de) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf-antikörper und verfahren zu ihrer verwendung
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2004074321A2 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
DE602004030535D1 (de) 2003-02-19 2011-01-27 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070042184A1 (en) 2003-08-22 2007-02-22 Danisco A/S Microcapsules
WO2005062955A2 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
ES2338344T3 (es) 2004-04-07 2010-05-06 Rinat Neuroscience Corporation Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
EP1789593B1 (de) 2004-07-09 2017-03-15 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Lösliche formen von hendra-virus-g-glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588295C (en) 2004-11-23 2013-10-22 Neuromolecular Pharmaceuticals, Inc. Method and composition for administering an nmda receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
EP1865981A2 (de) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CA2615615A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co., Ltd. Anti-cd26 antibodies and methods of use thereof
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
US7935342B2 (en) 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
RU2461572C2 (ru) 2006-06-07 2012-09-20 Биоэллаенс К.В. Антитела, распознающие содержащий углеводы эпитоп на cd-43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения
EP2035035A2 (de) 2006-06-09 2009-03-18 Novartis AG Immunogene zusammensetzungen für streptococcus agalactiae
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
WO2008116032A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions and methods for inhibiting tumor cell growth
EP2155777A2 (de) 2007-04-10 2010-02-24 The Administrators of the Tulane Educational Fund Lösliche und membranverankerte formen von proteinuntereinheiten des lassavirus
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
EP2245063B1 (de) 2007-12-18 2015-08-26 BioAlliance C.V. Antikörper, die ein kohlenhydrathaltiges, auf krebszellen exprimiertes epitop auf cd-43 und cea erkennen und verfahren zu deren verwendung
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
EP2403526B1 (de) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia-antigene
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CA2767536A1 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
PL2464658T3 (pl) 2009-07-16 2015-03-31 Novartis Ag Immunogeny z Escherichia coli o zniesionej toksyczności
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
TWI552760B (zh) 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗－ｉｌ－７受體抗體及方法
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
WO2014008263A2 (en) 2012-07-02 2014-01-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Paramyxovirus and methods of use
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
BR112015010722A2 (pt) 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
JP2016520058A (ja) 2013-05-07 2016-07-11 ライナット ニューロサイエンス コーポレイション 抗グルカゴン受容体抗体およびその使用方法
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
BR112016002008B1 (pt) 2013-08-02 2021-06-22 Pfizer Inc. Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
MY196625A (en) 2015-04-13 2023-04-23 Pfizer Therapeutic Antibodies and Their Uses
CA2993026A1 (en) 2015-07-21 2017-01-26 Dyax Corp. A monoclonal antibody inhibitor of factor xiia
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
EP3325010B1 (de) 2015-07-23 2023-06-21 The Regents of The University of California Antikörper gegen gerinnungsfaktor xia und verwendungen davon
NZ739871A (en) 2015-08-19 2022-05-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
CN113896789A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
JP6661319B2 (ja) * 2015-09-28 2020-03-11 小林製薬株式会社 リポソーム
CA2946113A1 (en) 2015-10-23 2017-04-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
EP3397253A1 (de) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit krämpfen
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
TW201936640A (zh) 2016-01-21 2019-09-16 美商輝瑞股份有限公司 對表皮生長因子受體變異體ｉｉｉ具特異性之抗體類及彼等之用途
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
KR20190124753A (ko) 2017-03-03 2019-11-05 리나트 뉴로사이언스 코프. 항-gitr 항체 및 이의 사용 방법
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
WO2018220584A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Antibodies specific for flt3 and their uses
JP7034183B2 (ja) 2017-06-13 2022-03-11 ボストンジーン コーポレイション 免疫チェックポイント遮断療法に対するレスポンダー及び非レスポンダーを特定するためのシステム及び方法
JP2020527558A (ja) 2017-07-13 2020-09-10 マサチューセッツ インスティテュート オブ テクノロジー シナプス機能を増強するためのｈｄａｃ２−ｓｐ３複合体の標的化
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
EP3692370A2 (de) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Artikel und verfahren zur personalisierten krebstherapie
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
MX2020012539A (es) 2018-05-23 2021-02-16 Pfizer Anticuerpos especificos para cd3 y sus usos.
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3152623A1 (en) 2019-10-11 2021-04-15 Richard D. Cummings Anti-tn antibodies and uses thereof
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
EP4182346A1 (de) 2020-07-17 2023-05-24 Pfizer Inc. Therapeutische antikörper und deren verwendungen
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2022232615A1 (en) 2021-04-29 2022-11-03 Bostongene Corporation Machine learning techniques for estimating tumor cell expression complex tumor tissue
WO2023012627A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2024015561A1 (en) 2022-07-15 2024-01-18 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
CH624011A5 (de) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
EP0199362A3 (de) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System und Vorrichtung zur verzögerten und stossweisen Freisetzung biologisch aktiver Substanzen
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes

Also Published As

Publication number Publication date
CN1055663A (zh) 1991-10-30
WO1991014445A1 (en) 1991-10-03
FI104464B (fi) 2000-02-15
ATE123412T1 (de) 1995-06-15
JP3461000B2 (ja) 2003-10-27
ES2073164T3 (es) 1995-08-01
NZ237464A (en) 1995-02-24
PT97101A (pt) 1991-11-29
EP0524968A4 (en) 1993-03-24
DK0524968T3 (da) 1995-07-31
NO923624L (no) 1992-09-17
EP0524968A1 (de) 1993-02-03
KR100203223B1 (ko) 1999-06-15
NO923624D0 (no) 1992-09-17
JPH05507680A (ja) 1993-11-04
CA2078666C (en) 2001-10-02
DE69110281T2 (de) 1995-11-09
AU655177B2 (en) 1994-12-08
FI924193A (fi) 1992-09-18
ZA911974B (en) 1994-08-22
CA2078666A1 (en) 1991-09-22
PT97101B (pt) 1998-08-31
EP0524968B1 (de) 1995-06-07
IE910911A1 (en) 1991-09-25
IL97615A (en) 1995-06-29
IE62772B1 (en) 1995-02-22
SA93130496B1 (ar) 2004-08-14
NO304576B1 (no) 1999-01-18
IL97615A0 (en) 1992-06-21
FI924193A0 (fi) 1992-09-18
RU2120795C1 (ru) 1998-10-27
AU7580691A (en) 1991-10-21
CN1053101C (zh) 2000-06-07

Similar Documents

Publication Publication Date Title
DE69110281D1 (de) Aus einem nichteinheitlichen bläschen bestehende liposomen.
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
ATE20574T1 (de) Pulverfoermige mischung von lipiden und hydrophoben bestandteilen, verfahren zu deren herstellung, hydratierte lamellare lipide phasen und verfahren zur herstellung, pharmazeutische oder kosmetische mittel die hydratierte lamellare lipide phasen enthalten.
DE3577851D1 (de) Inositoltriphosphat, verfahren zu seiner herstellung und dieses enthaltende zubereitung.
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
SE8103843L (sv) Farmaceutisk mixtur
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
FR2341578A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation ainsi que les compositions therapeutiques les contenant
PT71408A (de) Verfahren zur herstellung von 1-alkadien-2,4-yl-2-hidroxymethyl-3,4,5-trimydroxypiperidinen mit wirkung uber die kohlehydraten und/oder fettwechsel und von diesen verbindungen enthaltenden pharmazeutischen und/oder tierartzleichen praparaten
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
SE8102456L (sv) Farmaceutisk komposition for oral administering och innehallande cytidindifosfokolin
DE3586194T2 (de) Bioemulgatoren enthaltende kosmetische und pharmazeutische zusammensetzungen.
SE9002501L (sv) Mono(2-ammonium-2-hydroximetyl-1,3-propandiol)(2r,cis)-1,2-epoxipropylfosfonat med foerbaettrade stabilitets och bearbetningse genskaper
ATE40793T1 (de) Pharmazeutisches praeparat zur therapeutischen behandlung von rheumatischen erkrankungen.
BE884356A (fr) Nouveaux derives de type methylene-3 azetidine utiles comme medicaments et compositions therapeutiques les contenant
PT71308A (en) Process for the preparation of new 3,4,5-trihidrocy-piperidine derivatives with pharmaceutical and/or veterinary effect
AT354635B (de) Verfahren zur herstellung klarer , stabiler, waesseriger oder waesserig-alkoholischer loesungen fettloeslicher parfuemoele oder fettloeslicher arzneimittelwirkstoffe
IL82925A0 (en) Tetrahydrobenzothiazoles,their preparation and pharmaceutical compositions containing them
FR2521142B1 (fr) Nouveaux derives n-methanesulfonique de la demethyl-3-o istamycine b, leur preparation et compositions therapeutiques en contenant
SE8503447L (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
IT8167041A0 (it) Derivati di 1 fenil 4 morfolino 1buten 3 olo procedimento per la loro preparazione e loro uso farmaceutico
FR2363562A1 (fr) Nouveaux derives du 5-fluorouracile, utiles notamment comme agents anticancereux et leur procede de preparation
ATE135T1 (de) 2-substituierte-3-heterocycloindole, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
RU1216844C (ru) Способ стимул ции охоты у крупного рогатого скота

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SKYEPHARMA INC., SAN DIEGO, CALIF., US

8327 Change in the person/name/address of the patent owner

Owner name: PACIRA PHARMACEUTICALS,INC., SAN DIEGO, CALIF., US